Correlation Engine 2.0
Clear Search sequence regions


  • 5- fluorouracil (12)
  • antitumor (4)
  • cancers (1)
  • colon cancer (1)
  • local (1)
  • patients (1)
  • pharmacists (1)
  • plga (4)
  • polymer (1)
  • thymoma (1)
  • vitro (1)
  • w 5 (1)
  • Sizes of these terms reflect their relevance to your search.

    The aim of this study was to formulate a biodegradable implant capable of imparting local antitumor activity through the sustained release of the chemotherapeutic agent, 5-fluorouracil (5-FU). Thus, injectable pellets (<1.2 mm diameter) made from poly(lactide co-glycolide) (PLGA) and loaded with 5-FU at varying drug:polymer ratios were fabricated using hot-melt extrusion and tested for their ability to provide sustained release of 5-FU in in vitro and in vivo settings. In addition, these formulations were compared against soluble 5-FU for their antitumor activity in vivo as well as for their toxicity. It was demonstrated that the release rate of 5-FU from PLGA pellets was directly related to the percentage of 5-FU in the pellets. PLGA pellets loaded with 50% w/w 5-FU exhibited comparable, and significantly enhanced, antitumor activity (as measured by tumor volumes and survival) in vivo in a thymoma and colon cancer model, respectively, when compared to an equivalent bolus dose (120 mg/kg) of soluble 5-FU. We concluded that 5-FU-loaded PLGA pellets were more effective and specifically less erythrotoxic than 5-FU bolus injections and therefore may prove to be of benefit as an intraoperative adjunct therapy for patients with cancers that are sensitive to 5-FU and who are undergoing tumor resection. Copyright © 2017 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

    Citation

    Nattawut Leelakanok, Sean M Geary, Aliasger K Salem. Antitumor Efficacy and Toxicity of 5-Fluorouracil-loaded Poly(Lactide Co-glycolide) Pellets. Journal of pharmaceutical sciences. 2017 Oct 12


    PMID: 29031952

    View Full Text